Spyre Therapeutics (SYRE) Operating Income (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Operating Income came in at -$45.6 million in Q1 2026, up 14.8% YoY from -$39.8 million in Q1 2025, and up 20.17% on a QoQ basis from -$57.2 million in Q4 2025.
Spyre Therapeutics (SYRE) Operating Income (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Operating Income data on file, last reported at -$45.6 million in Q1 2026.
- Quarterly Operating Income rose 14.8% year-over-year to -$45.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$201.6 million (up 5.94% YoY) and the FY2025 annual result came in at -$209.6 million, changed 0.48% from the prior year.
- Operating Income advanced to -$45.6 million in Q1 2026, from -$57.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$18.3 million in Q3 2023 to a low of -$159.2 million in Q2 2023.
- A 5-year average of -$46.5 million and a median of -$45.6 million in 2026 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income plunged 610.19% — and 2024, when it surged 72.28%.
- Tracing SYRE's Operating Income over 5 years: stood at -$19.2 million in 2022, then plunged by 139.61% to -$45.9 million in 2023, then slumped by 33.41% to -$61.3 million in 2024, then rose by 6.66% to -$57.2 million in 2025, then gained by 20.17% to -$45.6 million in 2026.
- The last three Operating Income figures came in at -$45.6 million (Q1 2026), -$57.2 million (Q4 2025), and -$56.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | -41.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.64 Mn |
| Mar 31, 2026 | -45.64 Mn |
| Dec 31, 2025 | -57.17 Mn |
| Sep 30, 2025 | -56.89 Mn |
| Jun 30, 2025 | -41.94 Mn |
| Mar 31, 2025 | -53.57 Mn |
| Dec 31, 2024 | -61.25 Mn |
| Sep 30, 2024 | -55.39 Mn |
| Jun 30, 2024 | -44.15 Mn |
| Mar 31, 2024 | -47.77 Mn |
| Dec 31, 2023 | -45.91 Mn |
| Sep 30, 2023 | -18.34 Mn |
| Jun 30, 2023 | -159.25 Mn |
| Mar 31, 2023 | -18.81 Mn |
| Dec 31, 2022 | -19.16 Mn |
| Sep 30, 2022 | -18.76 Mn |
| Jun 30, 2022 | -22.42 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.44 Mn |
| Sep 30, 2021 | -20.29 Mn |